Skip to main content
Journal cover image

Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype.

Publication ,  Journal Article
Reason, EH; Thomas, SM; Chanenchuk, T; Botty van den Bruele, AM; DiNome, ML; Hwang, ES; Parrish, KM; Wang, T; Plichta, JK; Thomas, A; Chiba, A ...
Published in: Ann Surg Oncol
October 2025

INTRODUCTION: Metaplastic breast cancer (MpBC) is a rare breast cancer subtype historically less responsive to neoadjuvant chemotherapy (NAC), regardless of receptor status. Given increasing NAC administration in recent years, we analyzed contemporary treatment patterns and outcomes of patients with MpBC. METHODS: Patients with MpBC were selected (2012-2020) from the National Cancer Database (NCDB). Patient characteristics were compared by receptor subtype. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; log-rank tests were used to compare groups. Cox proportional hazard models were used to estimate the association of demographic and clinicopathologic variables with OS after adjustment. RESULTS: Among 4,601 patients (median age, 64 years) with MpBC, 72.7% were triple negative (n = 3,344), 21.6% HR+/HER2- (n = 995), and 5.7% HER2+ (n = 262). More HER2+ patients received NAC (34.4%) than TN (20.6%) or HR+/HER- (16%, p < 0.001), but overall use of NAC remained low (20.4%). Unadjusted OS did not differ by receptor subtype or stage. Of those who received NAC, HER2+ patients had double the pCR rate (20%) compared with triple negative (9.1%) and HR+/HER2- (10.1%, p = 0.006). Adjuvant chemotherapy was associated with improved unadjusted OS at all timepoints, whereas NAC showed no survival benefit at 1 year and 3 years, a trend consistent across receptor subtypes. After adjustment, adjuvant chemotherapy remained associated with improved OS (HR 0.69, 95% CI 0.59-0.8). CONCLUSIONS: Neoadjuvant chemotherapy administration and pCR rates remain low for MpBC, and NAC is not associated with OS, supporting the treatment approach of upfront surgery and adjuvant chemotherapy. Further investigation is needed into novel systemic therapies to determine pCR rates and impact on OS.

Duke Scholars

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

October 2025

Volume

32

Issue

11

Start / End Page

8496 / 8511

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Survival Rate
  • Receptors, Progesterone
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reason, E. H., Thomas, S. M., Chanenchuk, T., Botty van den Bruele, A. M., DiNome, M. L., Hwang, E. S., … Rosenberger, L. H. (2025). Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype. Ann Surg Oncol, 32(11), 8496–8511. https://doi.org/10.1245/s10434-025-17938-x
Reason, Ellery H., Samantha M. Thomas, Tori Chanenchuk, Astrid M. Botty van den Bruele, Maggie L. DiNome, E Shelley Hwang, Kendra Modell Parrish, et al. “Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype.Ann Surg Oncol 32, no. 11 (October 2025): 8496–8511. https://doi.org/10.1245/s10434-025-17938-x.
Reason EH, Thomas SM, Chanenchuk T, Botty van den Bruele AM, DiNome ML, Hwang ES, et al. Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype. Ann Surg Oncol. 2025 Oct;32(11):8496–511.
Reason, Ellery H., et al. “Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype.Ann Surg Oncol, vol. 32, no. 11, Oct. 2025, pp. 8496–511. Pubmed, doi:10.1245/s10434-025-17938-x.
Reason EH, Thomas SM, Chanenchuk T, Botty van den Bruele AM, DiNome ML, Hwang ES, Parrish KM, Wang T, Plichta JK, Thomas A, Chiba A, Rosenberger LH. Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype. Ann Surg Oncol. 2025 Oct;32(11):8496–8511.
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

October 2025

Volume

32

Issue

11

Start / End Page

8496 / 8511

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Survival Rate
  • Receptors, Progesterone
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged